Xaliproden

Drug Profile

Xaliproden

Alternative Names: SR 57746; SR 57746A; Xaliproden hydrochloride; xaliprodene; Xaprila

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Naphthalenes; Neuroprotectants; Nootropics; Pyridines; Small molecules
  • Mechanism of Action Nerve growth factor stimulants; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Cancer pain; Multiple sclerosis

Most Recent Events

  • 29 Jul 2009 Discontinued - Phase-III for Cancer pain in Australia (PO)
  • 29 Jul 2009 Discontinued - Phase-III for Cancer pain in Canada (PO)
  • 29 Jul 2009 Discontinued - Phase-III for Cancer pain in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top